GPX1 and cancer: It has been reported that overexpression of metallothionein confers resistance to anti-cancer drugs (Kelley et al., 1988); GPX1 promotes cisplatin resistance via ROS-Induced activation of PI3K/AKT pathway in non-small cell lung cancer (Chen et al., 2019).